2 Results for "

Docetaxel-d5

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "Docetaxel-d5" in MCE Product Catalog:

Cat. No.: HY-W653942
Synonyms: RP-56976-d5
Docetaxel-d5 (RP-56976-d5) is the deuterated-labeled Docetaxel (HY-B0011). Docetaxel (RP-56976) is an orally active tubulin stabilizer with antitumor activity. Docetaxel is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel can be used in cancer-related research [5].
loading...
    loading...
Cat. No.: HY-B0011AS
Synonyms: RP-56976-d5 trihydrate
Docetaxel-d5 trihydrate (RP-56976-d5 trihydrate) is the deuterated-labeled Docetaxel trihydrate (HY-B0011A). Docetaxel Trihydrate (RP-56976 Trihydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel Trihydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel Trihydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel Trihydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel Trihydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel Trihydrate can be used in cancer-related research [5].
loading...
    loading...